MJFF-Led Publication Establishes Framework to Prioritize and Advance Parkinson’s Therapeutic Targets

Milan, Italy – Prioritizing and selecting emerging therapeutic targets remains a critical challenge across the life sciences industry, particularly in complex neurodegenerative diseases such as Parkinson’s disease (PD). To address this, The Michael J. Fox Foundation for Parkinson’s Research (MJFF) launched the Targets to Therapies (T2T) initiative — an industry- and investor-led effort to identify, de-risk, and accelerate the most promising PD therapeutic targets toward development.

Today, MJFF and its collaborators announce a major milestone in this initiative, marked by the publication of a foundational paper, “A community-led initiative to de-risk and advance Parkinson’s disease therapeutic targets,” in npj Parkinson’s Disease journal.

Golgi Neurosciences was proud to contribute as an active member of the T2T community, bringing its expertise to the collaborative effort to evaluate and refine the target list. By working alongside leaders from academia, industry, and venture, Golgi helped shape a process designed to advance therapeutic innovation in PD.

Read the full publication here.